NICE set to recommend alitretinoin
This article was originally published in Scrip
Executive Summary
NICE, the health technology assessment agency for the national health service in England and Wales, has made changes to its draft guidance on using Basilea Pharmaceutica's Toctino (alitretinoin) in the treatment of adults with severe chronic hand eczema but it is still preparing to recommend the product as cost-effective.
You may also be interested in...
Cervarix link to UK girl's death "unlikely"
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Generic Topamax launched in European markets
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
NICE confirms limits on Alimta for lung cancer
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.